News & Updates
Filter by Specialty:
KEEPsAKE findings boost risankizumab efficacy, safety for PsA
In individuals with psoriatic arthritis (PsA) who have inadequate response or intolerance to ≥1 csDMARD*, the monoclonal antibody risankizumab significantly improved manifestations of PsA, according to the 24-week findings of the phase III KEEPsAKE 1 trial.
KEEPsAKE findings boost risankizumab efficacy, safety for PsA
24 Jan 2022
Osteoporosis drug holidays tied to small rise in hip fracture risk
The risk for hip fracture slightly increases following osteoporosis drug holidays after long-term therapy with risedronate compared with alendronate, a study has found, adding that future research must examine how best to lessen such risk.
Osteoporosis drug holidays tied to small rise in hip fracture risk
21 Jan 2022
Are pregnant women with rheumatic disease at risk of poor COVID-19 outcomes?
Pregnant women with rheumatic disease and COVID-19 show favourable outcomes, but data are limited by the small sample size and methodology, reports a study.
Are pregnant women with rheumatic disease at risk of poor COVID-19 outcomes?
20 Jan 2022
Anxiety, depressive symptoms in JIA tied to pain, stress
Moderate to severe symptoms of anxiety and depression have been reported in about one-fourth of children with juvenile idiopathic arthritis (JIA), according to a study. Such symptoms are associated with pain and stress, but not with other disease manifestations.
Anxiety, depressive symptoms in JIA tied to pain, stress
19 Jan 2022
Add-on duloxetine exerts null effect on chronic osteoarthritis pain
Adding duloxetine to usual care does not appear to produce significant relief from chronic osteoarthritis pain as compared with usual care alone, a study has found.